Your browser doesn't support javascript.
Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19.
Parums, Dinah V.
  • Parums DV; Scientific Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.
Med Sci Monit ; 27: e935624, 2021 Dec 01.
Article in English | MEDLINE | ID: covidwho-1547798
ABSTRACT
In 2021, data from global disease monitoring and infection surveillance programs have shown that vaccination programs have reduced the incidence of SARS-CoV-2 infection and hospitalization and mortality rates. Currently, the US Centers for Disease Control and Prevention (CDC) identifies a fully vaccinated individual as being ≥14 days after the completion of all the recommended doses of a COVID-19 vaccine that has been authorized by the US Food and Drug Administration (FDA). A partially vaccinated individual is <14 days following primary vaccination or has not completed the vaccination program. Clinical studies and data on the vaccine status of populations have identified breakthrough COVID-19 cases in fully vaccinated individuals at 14 or more days after completing the recommended dose of an authorized SARS-CoV-2 vaccine. This Editorial presents an update on what has been learned in the past year on SARS-CoV-2 vaccine responses and breakthrough COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Med Sci Monit Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: MSM.935624

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Med Sci Monit Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: MSM.935624